Clinical Trial Update: A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of BMS-986253 in combination with nivolumab or nivolumab plus ipilimumab in advanced cancers has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Melanoma

Drugs mentioned

• BMS-986253 (BMS-986253)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Cancer, Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-06-19